A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Navitoclax (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors AbbVie
- 31 Jan 2018 Planned End Date changed from 10 Apr 2020 to 8 Jul 2020.
- 03 Nov 2017 Planned End Date changed from 25 Mar 2020 to 10 Apr 2020.
- 03 Nov 2017 Status changed from not yet recruiting to recruiting.